When people hear the word 'testosterone,' the same image often comes to mind: physical strength, building muscle and hitting personal records in the gym. But that's not the full picture. Low testosterone impacts nearly 20 million men1 2 in the US, and for those affected, it can mean lower energy, reduced lean muscle, increased fat, lower sex drive, erectile dysfunction, and even depressed mood. Low testosterone is also a notable biomarker associated with increased risks of important men’s health issues, like metabolic syndrome, diabetes, obesity, and cardiovascular disease.
Unfortunately, many men don't recognize the symptoms or feel too much stigma to bring it up with their healthcare provider, and never get tested. That’s a missed opportunity to help affected men proactively address their health and to feel better.
Fortunately, things are changing. A new survey commissioned by Hims of 2,000 U.S. men ages 18 and older found men are talking more openly about hormone health and how it changes as they age. When we asked men what they actually want, 79% of men surveyed say more energy is a higher priority than more muscle,3 so they can show up more fully at work, in their hobbies and with the people who matter most.
But here’s the problem. The same Hims study shows fewer than half of men surveyed (45%) say they're familiar with specific low T treatments.4 As a practicing men’s health physician for more than 15 years, I've made it my mission to help men close that gap.
That’s why today, Hims is introducing access to injectable and oral testosterone replacement therapy. This is the largest and most important expansion to date of our men’s health program, and here’s what we’re offering:
Injectable TRT is available in both compounded and commercial formulations.
The oral TRT option, Kyzatrex®, is FDA-approved and has been shown to help up to 96% of men reach normal testosterone levels in just 90 days, no injections required.***
These new options build on Hims’ existing Testosterone Rx+ treatment, which includes enclomiphene, an ingredient shown to double testosterone levels^ by boosting the body’s natural hormone production. Since introducing its testosterone offering, Hims has focused on reaching the many men living with low T, building an experience around at-home blood collection and provider-guided treatment that adapts over time. That approach is resonating. As of the second quarter, testosterone was scaling faster than any other specialty outside of weight loss, just three quarters after its launch.%
Many men with low testosterone go undiagnosed, often because getting tested traditionally meant booking an appointment, going to a lab, and raising a sensitive topic in person. Hims built its clinical care experience to remove those access barriers while preserving clinical rigor and quality. Every customer begins with a detailed medical intake that assesses symptoms and screens for risk factors. They then collect a blood sample at home with the Tasso® device, an FDA-cleared, push-button capillary blood collector worn on the upper arm, with no lab visit or venous draw required. From that single, small sample, Hims’ labˣ tests 22 biomarkers, including total and free testosterone, SHBG, an advanced lipid panel, and glycemic markers, giving providers a far fuller picture of a man’s health than a standalone testosterone test. A licensed provider reviews symptoms, health history, and lab results in a live visit, and treatment is only prescribed when it’s medically appropriate. For those who begin treatment, ongoing assessments, follow-up lab testing, and continued access to a support team helps customers and their providers track progress and adjust care over time.
With injectable and oral testosterone now added to our previously available enclomiphene-based treatments , our partnered clinicians can now offer a full suite of personalized treatments to men affected by low T.
Treating testosterone deficiency isn't just about improving a lab result, it's about making sure eligible men have the support they need to feel strong, energized, and healthy. From support with energy and lean muscle to improved sexual health, these new treatments can help men perform at their peak and show up fully in the moments that count.
For more information, visit https://www.hims.com/testosterone.
1 Mulligan, T., Frick, M. F., Zuraw, Q. C., Stemhagen, A., & McWhirter, C. (2006). Prevalence of hypogonadism in males aged at least 45 years: the HIM study. International journal of clinical practice, 60(7), 762–769. https://doi.org/10.1111/j.1742-1241.2006.00992.x
2 National Population by Characteristics: 2020-2022. Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States: April 1, 2020 to July 1, 2022 (NC-EST2022-SYAEXN). U.S. Census Bureau. https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html. Accessed 8/11/23
3 Based on August 2026 external survey data of 2,000 U.S. men ages 18+. Respondents were asked which they prioritize more in their life: more energy or more muscle. The research was commissioned by Hims & Hers Health, Inc. and conducted by Culture Co-op.
4 Based on August 2026 external survey data of 2,000 U.S. men ages 18+. 45% selected at least one of seven listed low testosterone treatments they were familiar with. The research was commissioned by Hims & Hers Health, Inc. and conducted by Culture Co-op.
* National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 441404, Testosterone Cypionate. https://pubchem.ncbi.nlm.nih.gov/compound/Testosterone-Cypionate
** Schulte-Beerbühl, M., & Nieschlag, E. (1980). Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertility and sterility, 33(2), 201–203. https://www.sciencedirect.com/science/article/pii/S0015028216445437
*** Bernstein, J. S., & Dhingra, O. P. (2024). A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product. Therapeutic advances in urology, 16, 17562872241241864. https://doi.org/10.1177/17562872241241864
^ Thomas, J., Suarez Arbelaez, M. C., Narasimman, M., Weber, A. R., Blachman-Braun, R., White, J. T., Ledesma, B., Ghomeshi, A., Jara-Palacios, M. A., & Ramasamy, R. (2023). Efficacy of Clomiphene Citrate Versus Enclomiphene Citrate for Male Infertility Treatment: A Retrospective Study. Cureus, 15(7), e41476. https://doi.org/10.7759/cureus.41476
% As of Q2, 2026
Cautionary Note Regarding Forward-Looking Statements:
This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “project,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to the changes in our product or offering mix, the timing and market acceptance of any new products or offerings, the pricing of any new products or offerings, the timing and anticipated effect of any collaborations, our market opportunity, the growth of certain of our specialties, our ability to innovate on and expand the scope of our offerings and experiences, and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, delays in offering development; failure of offerings to perform as expected; limited market acceptance of new offerings; inability to obtain or maintain regulatory approvals; changes in healthcare, consumer protection or privacy laws; increased scrutiny from regulators; competitive product launches; challenges in manufacturing, distribution or supply chain; higher than anticipated launch costs; shifts in consumer spending or behavior; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission (the “Commission”).
Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of September 10, 2025. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.
We may include statements and information in this communication concerning our industry and the markets in which we operate, including our market opportunity, which are based on information from independent industry organizations and other third-party sources (including industry publications, surveys and forecasts). While we believe these third-party sources to be reliable as of the date of this communication, we have not independently verified any third-party information and such information is inherently imprecise.
